NDs are multifactorial complex disorders with genetics playing a crucial role in their development.
The challenge of their early detection and precise diagnosis is ever more pressing. Traditional diagnostic methods are often invasive, such as cerebrospinal fluid (CSF) sampling, or costly, such as PET scans.
Thus, the demand for a less invasive, blood-based test that can accurately diagnose NDs early, aid in drug development, and inform treatment choices is significant.
NeuroDeGene® is a solution to this challenge, offering an innovative genetic panel aimed at the early detection and prognosis of various NDs.
This panel taps into the genetic architecture underlying NDs while also meeting the critical need for less invasive diagnostic approaches.

The NeuroDeGene® panel is a DNA-targeted sequencing kit developed in partnership with Celemics, Inc., transforming the diagnosis and management of NDs, by identifying SNPs and INDELs linked to these conditions.
It creates predictive models for diseases that are historically difficult to diagnose by leveraging cutting-edge sequencing technologies, bioinformatics pipelines, and machine learning.
It provides significant benefits for diagnosing and prognosticating NDs, supporting clinical projects, and leading to individualized treatment plans.
It includes over 15,000 variants across 19 diseases, focusing particularly on non-coding variants, which make up about 70% of the panel and are crucial to disease development.